Want to see NRSN full AI Analyst Report?
Neurosense Therapeutics Ltd. (NRSN) Financial Statements
Neurosense Therapeutics Ltd. Financial Overview
Neurosense Therapeutics Ltd.'s market cap is currently $3.77M. The company's EPS TTM is $-8.91; its P/E ratio is -0.28; Neurosense Therapeutics Ltd. is scheduled to report earnings on ―, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.
| Mar 26 | Mar 25 | Mar 24 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Gross Profit | $ 0.00 | $ 0.00 | $ 0.00 | $ -89.00K | $ 0.00 |
| Operating Income | $ -11.09M | $ -9.90M | $ -12.05M | $ -13.55M | $ -5.59M |
| EBITDA | $ -11.11M | $ -9.88M | $ -9.64M | $ -12.23M | $ -2.88M |
| Net Income | $ -11.13M | $ -10.21M | $ -10.11M | $ -12.34M | $ -4.04M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 166.00K | $ 3.38M | $ 2.64M | $ 7.09M | $ 11.06M |
| Total Assets | $ 1.03M | $ 4.58M | $ 3.19M | $ 7.71M | $ 11.43M |
| Total Debt | $ 170.00K | $ 73.00K | $ 142.00K | $ 211.00K | $ 0.00 |
| Net Debt | $ 4.00K | $ -3.31M | $ -2.50M | $ -3.33M | $ -11.06M |
| Total Liabilities | $ 2.59M | $ 1.99M | $ 4.94M | $ 2.09M | $ 2.42M |
| Stockholders' Equity | $ -1.56M | $ 2.58M | $ -1.76M | $ 5.62M | $ 9.01M |
| Cash Flow | |||||
| Free Cash Flow | $ -7.68M | $ -10.14M | $ -8.38M | $ -7.66M | $ -1.56M |
| Operating Cash Flow | $ -7.67M | $ -10.13M | $ -8.35M | $ -7.59M | $ -1.54M |
| Investing Cash Flow | $ -8.00K | $ 1.00K | $ 3.47M | $ -3.54M | $ -17.00K |
| Financing Cash Flow | $ 4.43M | $ 10.91M | $ 3.98M | $ 3.69M | $ 11.90M |
Currency in USD